Insurance Denied Wegovy? Here's What to Do Next (Including $99/Month Options)
Got a Wegovy denial? You have more options than your insurer suggests. This guide walks you through every path forward — from appeals to $99/month compounded semaglutide that requires no insurance at all.
Written by Trimi Medical Team. Medically reviewed by Trimi Medical Review Board. This article is for informational purposes and does not replace personalized medical advice.
More on Cost & Access
Prior Authorization Denied for GLP-1? Your Options
What to do when prior auth fails, including compounded alternatives.
Is $99 Semaglutide Real?
Why compounded GLP-1 costs 90% less than brand-name.
Does Compounded Semaglutide Work as Well as Ozempic?
What the evidence shows about compounded vs. brand-name outcomes.
You did everything right. You saw your doctor, met the BMI criteria, and submitted a prior authorization for Wegovy. Then the denial letter arrived. If that describes your situation, you are in very good company — insurance denials for GLP-1 weight-loss medications affect millions of Americans every year, and most plans make the process deliberately difficult.
Here is the part your insurer is not advertising: a denial is not the end of the road. You have multiple paths forward, including filing a formal appeal, requesting a formulary exception, switching to a covered GLP-1, or starting treatment immediately through a cash-pay compounded semaglutide program at $99/month — no insurance required.
This guide covers every option in detail so you can decide what makes sense for your timeline, budget, and health goals.
Why Wegovy Gets Denied So Often
Understanding why your claim was denied is the first step to fixing it. Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management, but insurance coverage remains inconsistent across commercial plans, Medicare, and Medicaid. The denial reason on your letter determines your best path forward.
The four most common Wegovy denial reasons
1. Obesity-drug benefit exclusion
Your plan simply does not cover drugs used primarily for weight loss. This is the most common reason and one of the hardest to appeal — because the plan is following its own rules. Your best option here is usually a formulary exception (if you have a qualifying condition like type 2 diabetes) or switching to a cash-pay compounded option.
2. Failed prior authorization documentation
Your request was incomplete or did not include records that match the plan's specific criteria. This is the most fixable denial type — a resubmission with complete documentation often succeeds.
3. Does not meet stated criteria
The plan's records suggest you do not meet the BMI threshold (usually 30+, or 27+ with a qualifying comorbidity) or the plan requires documented prior treatment attempts. A well-prepared appeal with complete medical records resolves many of these denials.
4. Step therapy requirement
Your plan requires you to try a different medication or program first — often orlistat, phentermine, or a structured diet program — before it will cover Wegovy. Your provider can sometimes get this waived with documentation of contraindications or prior attempts.
Option 1: File a Formal Appeal
If your plan has a legitimate prior authorization process (not a blanket exclusion), a formal appeal is worth pursuing — especially if the denial was due to incomplete documentation. Appeals succeed roughly 30–50% of the time when submitted correctly.
What to include in your appeal packet
- The denial letter with the exact denial reason quoted
- Your plan's current formulary and obesity-drug policy language
- An updated letter of medical necessity from your prescriber that addresses the denial reason by name
- Recent weight, BMI, and body composition records
- Documentation of qualifying comorbidities (type 2 diabetes, hypertension, sleep apnea, high cholesterol)
- Records of prior weight-loss treatments — diets, programs, other medications — if your plan requires step therapy
- Any peer-reviewed studies or FDA labeling that directly contradicts the insurer's stated rationale
Appeals timeline to expect
- Standard internal appeal: 30–60 days for a decision
- Expedited appeal (urgent medical situation): 72 hours
- Second-level internal appeal (if available): additional 30–60 days
- External independent review: available after exhausting internal levels in most states
See our full guide on appealing GLP-1 insurance denials for a step-by-step process and a template appeal letter you can adapt for your situation.
Option 2: Request a Formulary Exception
Even if your plan has an obesity-drug exclusion, a formulary exception may be possible if Wegovy is being prescribed for a different qualifying indication — most commonly type 2 diabetes or cardiovascular risk reduction. Ozempic (the same molecule, semaglutide 0.5–2mg) has FDA approval for both, and many plans cover it for those indications while excluding Wegovy.
Your prescriber needs to frame the clinical case around the diabetes or cardiovascular indication rather than weight loss. This is legitimate when those conditions are present — it is not a workaround, it is documenting the medical picture accurately.
Learn more in our guide to GLP-1 prior authorization options.
Option 3: Start Compounded Semaglutide at $99/Month
This is the path most people do not know about when they get a Wegovy denial — and for many, it is the fastest and most practical option.
Compounded semaglutide contains the identical active ingredient as Wegovy at the same clinical doses. It is prepared by FDA-registered outsourcing facilities and PCAB-accredited compounding pharmacies, not by Novo Nordisk, which is why it costs $99/month at Trimi instead of $1,300+ for the brand-name version. No insurance required. No prior authorization. No denial letters.
What you get with Trimi's $99/month program
- Online health assessment reviewed by a board-certified provider within 24 hours
- Prescription for compounded semaglutide if clinically appropriate
- Medication shipped from an accredited pharmacy to your door in 5–7 business days
- Dose titration protocol matching the clinical schedule used in the STEP trials
- Ongoing provider access for dose adjustments and side-effect management
- No insurance, no prior auth, no denial — flat $99/month pricing
Many patients start compounded semaglutide immediately while their insurance appeal is still pending. If the appeal eventually succeeds, they can transition to brand-name Wegovy. If it does not, they have been on effective treatment the entire time without waiting.
Read our full explainer: Is $99 semaglutide real?
Option 4: Manufacturer Patient Assistance
Novo Nordisk offers the NovoCare Patient Assistance Program for uninsured or underinsured patients who meet income criteria. Eligibility requirements and benefit levels change, so check directly with NovoCare for current terms. These programs are useful but typically involve income documentation and multi-week approval timelines.
For a full comparison of cost reduction options, see every low-cost GLP-1 option in 2026.
Option 5: Explore a Different GLP-1 Your Plan Does Cover
Some plans cover Ozempic for diabetes even when they exclude Wegovy for weight loss — despite both containing semaglutide. Similarly, some plans cover Mounjaro or Zepbound (tirzepatide) under different criteria. Ask your prescriber whether another GLP-1 in the same drug class might be covered under your plan's formulary for a qualifying indication.
Trimi also offers compounded tirzepatide at $125/month if you want to explore the dual GIP/GLP-1 mechanism. Read our overview of how compounded GLP-1 medications compare to brand-name.
How to Decide Which Path Is Right for You
| Your situation | Best path |
|---|---|
| Denial was due to incomplete documentation | File an appeal with a complete packet — high success rate |
| Plan has a blanket obesity-drug exclusion | Formulary exception (if you have diabetes/CV risk) or compounded semaglutide $99/mo |
| You want to start treatment immediately | Compounded semaglutide — approval in 24 hours, delivery in 5–7 days |
| You want brand-name Wegovy long-term | Appeal + start compounded semaglutide while appeal is pending |
| Budget is the primary concern | Compounded semaglutide $99/mo — no insurance needed, no appeal hassle |
| You have type 2 diabetes alongside obesity | Ask prescriber about Ozempic coverage for diabetes indication |
Is Compounded Semaglutide as Effective as Wegovy?
This is the most common question from patients considering the switch. The short answer: the active ingredient is identical, so the clinical mechanism and expected outcomes are the same. The longer answer involves understanding what "compounded" means.
Wegovy and compounded semaglutide both contain semaglutide — a GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and promotes weight loss. The STEP-1 trial, which established Wegovy's clinical profile, used semaglutide 2.4mg weekly. Compounded semaglutide from Trimi's pharmacy follows the same dose titration schedule.
The difference is in the manufacturing pathway: Wegovy is made by Novo Nordisk in licensed commercial facilities; compounded semaglutide is prepared by accredited 503B outsourcing facilities or 503A compounding pharmacies using pharmaceutical-grade active pharmaceutical ingredient (API). Trimi partners with pharmacies that conduct third-party potency, sterility, and endotoxin testing on every batch.
For a detailed comparison, see does compounded semaglutide work as well as Ozempic?
Common Mistakes After a Wegovy Denial
- Assuming the denial is final and giving up on semaglutide treatment entirely
- Filing an appeal that does not quote the exact denial reason or plan language
- Waiting months for an appeal decision before exploring any other options
- Using a GoodRx coupon expecting to pay $99 (GoodRx reduces brand-name costs but Wegovy is still $800–900/month even with coupons)
- Buying semaglutide from unverified online sources without a provider relationship or quality verification
- Not knowing that compounded semaglutide from a licensed telehealth provider is legal, available, and priced at $99/month
Getting Started with Trimi After a Wegovy Denial
The process is intentionally simple because Trimi built it for exactly this situation — patients who have been denied insurance coverage and need a fast, affordable alternative.
- 1Complete a 10-minute online health assessment covering your medical history, current medications, and weight-loss goals
- 2A board-certified provider reviews your assessment and approves or discusses the prescription — typically within 24 hours
- 3Your compounded semaglutide is prepared and shipped from an accredited pharmacy
- 4Medication arrives in 5–7 business days — including injection supplies, a dose-titration schedule, and provider contact information
- 5Monthly refills at $99/month with ongoing provider access for adjustments
You can also read about how online GLP-1 prescriptions work in 2026 and how to get started without a wait list.
Frequently Asked Questions
My insurance denied Wegovy — is that the end of the road?
No. An insurance denial for Wegovy is extremely common and does not mean you cannot access semaglutide. You have several paths: file an appeal using the exact denial language, ask your provider to submit an updated prior authorization, explore a formulary exception, or switch to compounded semaglutide through a telehealth provider like Trimi for $99/month with no insurance required.
Why do insurers deny Wegovy so often?
Wegovy denials typically happen for four reasons: the plan has a blanket obesity-drug exclusion, you do not yet meet documented BMI or comorbidity criteria, prior authorization documents were incomplete, or the plan requires step therapy through other treatments first. Each denial type has a different fix — you need to know which one applies before responding.
What is compounded semaglutide and is it the same as Wegovy?
Compounded semaglutide contains the same active ingredient as Wegovy — semaglutide — at the same doses used in clinical trials. It is prepared by FDA-registered 503B outsourcing facilities and 503A compounding pharmacies rather than by Novo Nordisk. The clinical mechanism, weight-loss effect, and side-effect profile are the same. The main difference is price: compounded semaglutide starts at $99/month through Trimi versus $1,300+/month retail for Wegovy.
Do I need insurance for compounded semaglutide?
No. Compounded semaglutide through Trimi is a direct-pay program priced at $99/month. There is no prior authorization, no formulary, and no insurer to deny your claim. Your board-certified provider reviews your health profile online and, if appropriate, sends your prescription directly to an accredited compounding pharmacy that ships to your door.
Should I appeal my Wegovy denial or just switch to compounded?
That depends on your timeline and energy. Appeals take four to twelve weeks and succeed roughly 30–50% of the time when submitted correctly with complete documentation. If you want to start treatment now while your appeal is pending, compounded semaglutide lets you begin immediately at $99/month. Many patients do both: start compounded semaglutide right away while appealing for brand-name coverage.
What documentation do I need to appeal a Wegovy denial?
You need: the denial letter with the exact quoted denial reason, your current plan's formulary or obesity-drug policy language, an updated letter of medical necessity from your prescriber that directly addresses the denial reason, recent weight and BMI records, documentation of comorbidities like type 2 diabetes or sleep apnea, and records of any prior weight-loss treatments the plan requires. The appeal should quote the plan's own language back to the insurer.
How quickly can I start compounded semaglutide after a Wegovy denial?
Most Trimi patients receive provider approval within 24 hours of completing their online health assessment. Medication ships from our accredited pharmacy within 2–3 business days of approval and arrives within 5–7 business days. From Wegovy denial to first injection, the typical timeline is under two weeks.
Related Reading
Sources & References
- STEP 1 trial: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989–1002.
- FDA guidance on drug compounding regulations and 503B outsourcing facilities.
- KFF. Coverage of GLP-1s for Obesity Among Large Employers and Insurers. 2024.
- CMS memo on Medicare Part D coverage of anti-obesity medications.
- NABP compounding pharmacy accreditation standards (PCAB).
- FDA prescribing information for Wegovy (semaglutide injection 2.4mg).
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Trimi provides compounded GLP-1 medications through licensed healthcare providers — this article is educational and reflects our perspective as a provider in this space.